CancerNetwork®

“Every oncologist, every researcher, every IRB has got to know about that study.”

@DrMaurieMarkman, on why LACC tops his ranking of landmark gynecologic oncology trials on Double Blind.

Watch: youtube.com/watch?v=4KcWCX…

What’s one thing about hepatocellular carcinoma (HCC) you wish more of your colleagues knew? 🩺

At #TLM26 in Denver, we put that question to 4 liver cancer specialists: @DrHuangDQ, @AndrewMMoon, Laura Kulik, MD, and Neil Mehta, MD.

Hear what they had to say about awareness gaps in HCC care.

#HCC #LiverCancer #Hepatology #Oncology #TheLiverMeeting #AASLD

Up to a third of patients with MASLD-related HCC don’t have cirrhosis, so surveillance limited to cirrhosis misses them.

At #TLM2026, @DrHuangDQ of @NCIS_NUHS talked about how genetics, body composition, and multidisciplinary pathways should shape care.

cancernetwork.com/view/rethinkin…

#MASLD #LiverCancer #HCC

🚨 The latest edition of the Weekly Roundup is here!

📖 Check out this week's newsletter for a breakdown of our coverage from the @UPMCHillmanCC Radiation Oncology Symposium!

Subscribe on LinkedIn hubs.li/Q04DFwzy0

#oncology #RadOnc #cancer

MASLD is driving more liver cancer, and surveillance isn’t keeping up. Up to a third of ultrasounds in these patients may be low quality.

At #TLM2026, @SeragHashem of @bcmhouston talked about who needs HCC screening, the role of GLP-1 receptor agonists, and what comes next.

cancernetwork.com/view/building-…

#MASLD #LiverCancer #HCC